Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster
Phase of Trial: Phase III
Latest Information Update: 24 May 2017
At a glance
- Drugs GSK 1437173A (Primary)
- Indications Herpes zoster
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline
- 08 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Jun 2013 Planned End Date changed from 1 Apr 2015 to 1 Jan 2015 as reported by ClinicalTrials.gov.